News and Press Releases
ACG Packaging Materials GHG Commitment Validated and Approved by SBTi
May 7, 2025, Mumbai, India: ACG Packaging Materials, a leading global supplier of integrated manufacturing solutions for the pharmaceutical and nutraceutical industries, has taken a significant step forward in its...
Category: Manufacturing and Packing
Posted: May 7, 2025
Vetter Prioritises Continuity and Action in its Sustainability Efforts
May 6, 2025, Ravensburg, Germany – Vetter, a leading global contract development and manufacturing organization (CDMO) published its fourth annual sustainability report. The report shows that the family-owned business is...
Category: Manufacturing and Packing
Posted: May 7, 2025
Chiesi partners with Wirral Primary Care Collaborative to advance early detection of undiagnosed COPD
It is estimated that up to 5,000 people are living with undiagnosed COPD on the Wirral, where prevalence is more than 40% higher than the national average COPD is a...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Johnson & Johnson submits application to the European Medicines Agency for additional subcutaneous RYBREVANT▼(amivantamab) dosing regimens to treat patients with EGFR-mutated advanced non-small cell lung cancer
Application supports every-three-week (Q3W) and every-four-week (Q4W) SC amivantamab dosing regimens Subcutaneous (SC) amivantamab offers patients greater convenience with reduced administration time from hours to minutes and lower rates of...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025
Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months. 6 May 2025...
Category: Biotechnology, Clinical Trials, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: May 6, 2025
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell Factory for CAR-T therapy manufacturing
Agreement with Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) for the manufacturing of CAR-T therapies using Lakhesys Benchtop Cell Factory Partnership to demonstrate the...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: May 6, 2025
Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease
Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug...
Category: Manufacturing and Packing, Pharmaceutical
Posted: May 1, 2025
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) Regulatory and strategic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025
NICE recommends Yselty▼ (linzagolix) for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
1 May 2025 -- London, UK -- Theramex is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended NHS reimbursement of the extended indication...
Category: Other, Pharmaceutical
Posted: May 1, 2025
Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve
1 May 2025, Holmes Chapel, UK — Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), today announced that it has completed its first life cycle assessment (LCA) for...
Category:
Posted: May 1, 2025
Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA
Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...
Category: Other, Pharmaceutical
Posted: April 30, 2025
